BH3 Profiling for Chemosensitivity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, are often inefficient and ineffective due to a lack of personalized approaches, leading to adverse responses such as tumor lysis syndrome and variable drug efficacy in patients, necessitating a method to predict treatment outcomes and toxicity.
Innovation Solution
A method involving BH3 profiling, which determines the likelihood of adverse responses and therapeutic efficacy by isolating cancer cells, contacting them with BH3 peptides, detecting mitochondrial membrane permeabilization, and classifying patient responses based on BH3 protein profiles, including BAD, PUMA, BIM, and HRK, to guide treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is administered to treat cancer, then therapeutic efficacy may be achieved, but adverse responses such as tumor lysis syndrome and treatment-related toxicities occur
Solution Approach 1:
The patent applies preliminary action by performing BH3 profiling assays on patient tumor samples before chemotherapy administration. This pre-treatment assessment identifies patients at high risk for adverse events like tumor lysis syndrome, allowing clinicians to adjust treatment plans in advance to prevent or mitigate these harmful effects while maintaining therapeutic efficacy.
2Reliability
If personalized medicine approaches are implemented to predict treatment response, then adverse events can be identified and avoided, but diagnostic complexity and time requirements increase
Solution Approach 1:
The patent replaces complex clinical judgment and multiple diagnostic tests with a standardized BH3 profiling assay that measures mitochondrial membrane permeabilization in response to BH3 peptides. This substitution provides objective, quantitative data (priming scores) that simplify the diagnostic process while maintaining high prediction accuracy for treatment response and adverse event risk.
3Productivity
If BH3 profiling is performed to determine chemosensitivity, then treatment selection can be optimized, but additional time and resources are required for testing
Solution Approach 1:
The BH3 profiling assay is performed on archived tumor samples or fresh biopsy material obtained during routine diagnostic workup, before treatment decisions need to be made. By utilizing already-collected samples and providing rapid results, the assay minimizes additional time requirements while enabling optimized treatment selection based on individual patient chemosensitivity profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables personalized treatment decisions by predicting adverse events and therapeutic efficacy, improving patient outcomes by identifying suitable cancer treatments and avoiding toxicities, thereby enhancing treatment effectiveness and patient quality of life.
Implementation Method 1
contacting the cancer cell or specimen with one or more BH3 peptides; detecting a signal that indicates mitochondrial membrane permeabilization
Data Source
AI summary
The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.